Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 97 of 115 for:    "Viral Infectious Disease" | "Ledipasvir"

Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy (IFNfreeCOG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02469012
Recruitment Status : Unknown
Verified June 2015 by Arne Schaefer, University of Wuerzburg.
Recruitment status was:  Recruiting
First Posted : June 11, 2015
Last Update Posted : June 11, 2015
Sponsor:
Information provided by (Responsible Party):
Arne Schaefer, University of Wuerzburg

Brief Summary:
The present study evaluates neurocognitive performance as well as measures of mood, quality of life, and fatigue in patients with chronic hepatitis C infection. In a prospective longitudinal study design, included patients are monitored before, during, and in the long-term follow-up of interferon-free antiviral treatment (Sofosbuvir +/-Daclatasvir +/- Ribavirin or Sofosbuvir/Ledipasvir +/- Ribavirin). Main study goals are to compare post therapy results of sustained virologic responders to corresponding pretreatment values as well as to historic interferon-treatment patients without virological response. It is expected that HCV-associated neuropsychiatric symptoms and neurocognitive impairment is - at least in part - reversible by the successful application of modern IFN-free antiviral medication.

Condition or disease Intervention/treatment Phase
Hepatitis C, Chronic Drug: Combination #1 Drug: Combination #2 Drug: Combination #3 Drug: Combination #4 Drug: Combination #5 Not Applicable

Detailed Description:

Chronic hepatitis C is one of the most frequent infectious diseases worldwide and a major cause of chronic liver disease. At diagnosis, approximately 20 % of patients with chronic hepatitis C already have liver cirrhosis.

Therapy for hepatitis C has meanwhile reached a high level of efficacy and effectiveness: at present, about 90 % of patients treated with a combination of peginterferon alfa, ribavirin and sofosbuvir for up to 12 weeks will reach a sustained loss of hepatitis C virus.

Psychiatric side effects of interferon alfa are well known and may require dose reduction or even premature discontinuation of therapy.

As patients on interferon treatment sometimes report concentration or memory impairment that in some cases interferes considerably with their capacity to manage the requirements of everyday life, the investigators planned and intend to conduct a prospective and longitudinal study evaluating - among other parameters - neurocognitive performance before, during, and after therapy with an antiviral IFN-free therapy.

In previously performed scientific work, the investigators were able to show that interferon-based combination therapy of chronic hepatitis C may cause reversible impairment of neurocognitive performance during treatment period. Moreover, the investigators have recently demonstrated that successful IFN-based antiviral treatment (criterion: SVR, sustained virological response) leads to significant improvement of relevant aspects of attentional and neurocognitive performance. These results indicate that HCV-related neurocognitive impairment is potentially reversible.

Nevertheless, there are still open questions and important issues to be addressed in connection with this field of research, especially regarding several aspects IFN-free antiviral therapy:

Questions to be answered:

  • At least 12 months after the end of successfully performed IFN-free antiviral treatment - are psychometrically assessed parameters related to patients' quality of life, fatigue, neurocognitive performance, and mood significantly improved as compared to pretreatment (i.e., baseline) values?
  • At least12 months after the end of antiviral treatment, is there a significant difference between patients with and without sustained virological response (special to historical group of IFN-treated patients without a sustained virological response) with respect to neurocognitive performance, emotional state, fatigue and quality of life?
  • In the absence of a clinically significant liver damage in patients with chronic hepatitis C - does the mere presence of the hepatitis C virus have any significant influence on neurocognitive or attentional performance? Is it possible to confirm the respective findings yielded in the context of former interferon-based treatment regimens?
  • With the current and upcoming IFN-free treatment options - are there still any significant therapy-related changes in symptom areas such as neurocognitive performance, mood or fatigue?

Study Design:

Prospective monocentric study with a longitudinal repeated measures design including hepatitis C patients with indication for standard IFN-free antiviral therapy (sofosbuvir/daclatasvir +/- ribavirin; sofosbuvir/ledipasvir +/- ribavirin) and a long-term follow-up of quality of life, neurocognitive performance, fatigue, and emotional state. Planned sample size: n = 30 hepatitis C patients.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Evaluation of Quality of Life, Neurocognitive Performance, Fatigue, and Emotional State in HCV Patients Before, During, and in the (Long-term) Follow-up of an IFN-free Antiviral Therapy
Study Start Date : October 2014
Estimated Primary Completion Date : October 2016
Estimated Study Completion Date : April 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: IFN-free antiviral treatment
Combination #1 or Combination #2 or Combination #3 or Combination #4 or Combination #5
Drug: Combination #1
Sofosbuvir + Ribavirin
Other Name: Sofosbuvir + Ribavirin

Drug: Combination #2
Sofosbuvir + Daclatasvir
Other Name: Sofosbuvir + Daclatasvir

Drug: Combination #3
Sofosbuvir + Daclatasvir + Ribavirin
Other Name: Sofosbuvir + Daclatasvir + Ribavirin

Drug: Combination #4
Sofosbuvir + Ledipasvir
Other Name: Sofosbuvir + Ledipasvir

Drug: Combination #5
Sofosbuvir + Ledipasvir + Ribavirin
Other Name: Sofosbuvir + Ledipasvir + Ribavirin




Primary Outcome Measures :
  1. Change in Neurocognitive Performance (computerized TAP - Test Battery for Attentional Performance) [ Time Frame: evaluation time points are at baseline, after 4 weeks and 12 weeks of antiviral IFN-free treatment, four weeks and 12 months after the end of antiviral IFN-free therapy ]
    assessment of changes over treatment time (repeated measures design)


Secondary Outcome Measures :
  1. Change in Fatigue (Fatigue Impact Scale - FIS-D, questionnaire) [ Time Frame: evaluation time points are at baseline, after 4 weeks and 12 weeks of antiviral IFN-free treatment, four weeks and 12 months after the end of antiviral IFN-free therapy ]
    assessment of changes over treatment time (repeated measures design)

  2. Change in Health-Related Quality of Life (SF-36, questionnaire) [ Time Frame: evaluation time points are at baseline, after 4 weeks and 12 weeks of antiviral IFN-free treatment, four weeks and 12 months after the end of antiviral IFN-free therapy ]
    assessment of changes over treatment time (repeated measures design)

  3. Change in Emotional State (Hospital Anxiety and Depression Scale HADS, questionnaire) [ Time Frame: evaluation time points are at baseline, after 4 weeks and 12 weeks of antiviral IFN-free treatment, four weeks and 12 months after the end of antiviral IFN-free therapy ]
    assessment of changes over treatment time (repeated measures design)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with chronic hepatitis C and indication for interferon-free antiviral therapy.
  • Written informed consent to study participation, especially to long-term follow-up monitoring of quality of life, emotional state, fatigue, and neurocognitive performance after antiviral treatment.
  • Age of study participants: between 18 and 75 years.
  • At study entry, all participating patients need to have documented antibodies to HCV and circulating HCV-RNA as measured by reverse-transcription polymerase chain reaction (Cobas Amplicor HCV MonitorTM test, Roche Diagnostics)

Exclusion Criteria:

  • Insufficient knowledge of the German language or cognitive impairment (due* to the indispensable application of questionnaires and the TAP, test battery of attentional performance).
  • Age under 18 years or over 75 years
  • Coinfections such as hepatitis B virus or human immunodeficiency virus
  • Severe internal diseases (e.g., cancer, ischemic heart disease, autoimmune disease)
  • Major depressive disorder (according to DSM-IV criteria), psychosis, active intravenous drug use or alcohol abuse.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02469012


Contacts
Layout table for location contacts
Contact: Arne Schäfer, PhD +49931201402 ext 01 arne.schaefer@me.com
Contact: Michael R Kraus, MD, PhD +4986778801 ext 41 m.kraus@krk-bgh.de

Locations
Layout table for location information
Germany
Kreiskliniken Altötting-Burghausen, Medizinische Klinik II Recruiting
Burghausen, Bavaria, Germany, 84489
Contact: Michael R Kraus, MD, PhD    +4986778801 ext 41    m.kraus@krk-bgh.de   
Sponsors and Collaborators
University of Wuerzburg
Investigators
Layout table for investigator information
Principal Investigator: Michael R Kraus, MD, PhD Kreiskliniken Altötting-Burghausen, Burghausen, Germany

Publications of Results:
McQuillan GM, Alter MJ, Moyer LA, Lambert SB, Margolis HS. A population-based serologic study of hepatitis C virus infection in the United States. In: Rizetto M, Purcell RH, Gerin JL, Verne G (Eds.) Viral Hepatitis and Liver Disease. Turin, Italy: Edizioni Minerva Medica, 1997

Layout table for additonal information
Responsible Party: Arne Schaefer, PD Dr. Arne Schaefer, University of Wuerzburg
ClinicalTrials.gov Identifier: NCT02469012     History of Changes
Other Study ID Numbers: 228/14
First Posted: June 11, 2015    Key Record Dates
Last Update Posted: June 11, 2015
Last Verified: June 2015
Keywords provided by Arne Schaefer, University of Wuerzburg:
chronic hepatitis C
antiviral treatment
interferon-free
neurocognitive performance
emotional state
quality of life
Additional relevant MeSH terms:
Layout table for MeSH terms
Virus Diseases
RNA Virus Infections
Ledipasvir
Hepatitis C
Hepatitis C, Chronic
Hepatitis
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Flaviviridae Infections
Hepatitis, Chronic
Ribavirin
Antiviral Agents
Sofosbuvir
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents